Cost-effectiveness analysis of a transparent antimicrobial dressing for managing central venous and arterial catheters in intensive care units

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Maunoury, Franck ^a   Motrunich, Anastasiia ^a   Palka Santini, Maria ^b   Bernatchez, Stéphanie F ^c   Ruckly, Stéphane ^d   Timsit, Jean François ^d,e  

^a Technopôle de l'Université   (France)

^b 3M Deutschland GmbH   (Germany)

^c 3M COMPANY   (United States)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORHEXIDINE GLUCONATE; CHLORHEXIDINE; TOPICAL ANTIINFECTIVE AGENT;

ADULT; ARTERY CATHETER; ARTICLE; BLOOD VESSEL CATHETERIZATION; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TRANSPARENT DRESSING; AGED; ANALOGS AND DERIVATIVES; BANDAGE; CATHETER-RELATED INFECTIONS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; MARKOV CHAIN; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; VASCULAR ACCESS DEVICE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS, LOCAL; BANDAGES; CATHETER-RELATED INFECTIONS; CHLORHEXIDINE; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MARKOV CHAINS; MIDDLE AGED; PROBABILITY; VASCULAR ACCESS DEVICES;

EID: 84939161528     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130439     Document Type: Article

References (38)

1. Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S. Attributable morbidity and mortality of catheterrelated septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol. 1999;20:396-401. PMID:10395140
2. Renaud B, Brun-Buisson C. ICU-Bacteremia Study Group. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med. 2001;163:1584-90. PMID:11401878
3. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2011;39(4 Suppl 1):S1-34. doi:10.1016/j.ajic.2011.01.003 PMID:21511081.
4. Timsit JF, Dubois Y, Minet C, Bonadona A, Lugosi M, Ara-Somohano C, et al. New materials and devices for preventing catheter-related infections. Annals of Intensive Care. 2011;1:34. doi:10.1186/2110-5820-1-34 PMID:21906266
5. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet. 2000;355:1864-8. PMID:10866442
6. Coopersmith CM, Rebmann TL, Zack JE, Ward MR, Corcoran RM, Schallom ME, et al. Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit. Crit Care Med. 2002;30:59-64. PMID:11902288
7. Suetens C, Morales I, Savey A, Palomar M, Hiesmayr M, Lepape A, et al. European surveillance of ICU-acquired infections (HELICS-ICU): methods and main results. J Hosp Infect. 2007;65:171-3. PMID:17540265
8. Poujol I, Thiolet JM, Bernet C, Carbonne A, Dumartin C, Sénéchal H, et al. Notification of healthcareassociated infections, France, 2007-2009. BEH. 2010; October 2010:38-9.
9. Davidoff F. Heterogeneity Is Not Always Noise. JAMA. 2009;302(23):2580-6. doi:10.1001/jama.2009. 1845 PMID:20009058
10. Timsit JF, L'Hériteau F, Lepape A, Français A, Ruckly S, Venier AG, et al. A multicentre analysis of catheter-related infection based on a hierarchical model. Intensive Care Med. 2012;38(10):1662-72. PMID:22797354
11. Pronovost PJ, Goeschel CA, Colantuoni E, Watson S, Lubomski LH, Berenholtz SM, et al. Sustaining reductions in catheter related bloodstream infections in Michigan intensive care units: observational study. BMJ. 2010;340:c309. doi:10.1136/bmj.c309 PMID:20133365
12. Mermel LA. What is the predominant source of intravascular catheter infections? Clin Infect Dis. 2011;52(2):211-2. doi:10.1093/cid/ciq108 PMID:21288845
13. Timsit JF, Mimoz O, Mourvillier B, Souweine B, Garrouste-Orgeas M, Alfandari S, et al. Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. Am J Respir Crit Care Med. 2012;186(12):1272-8. doi:10.1164/rccm. 201206-1038OC PMID:23043083.
14. Timsit JF, Schwebel C, Bouadma L, Geffroy A, Garrouste-Orgeas M, Pease S, et al. Chlorhexidineimpregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults. J Am Med Assoc. 2009;301(12):1231-41.
15. French National Authority for Health. Choices in Methods for Economic Evaluation: a methodological guide. http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices-in-methods-for-economic-evaluation.pdf (2012). Accessed 15 Jul. 2013. 2012.
16. Maruotti A, Rocci R. A mixed non-homogeneous hidden Markov model for categorical data, with application to alcohol consumption. Stat Med. 2012;31:871-86. doi:10.1002/sim.4478 PMID:22302505
17. Nunes B, Natário I, Lucília Carvalho M. Nowcasting influenza epidemics using non-homogeneous hidden Markov models. Stat Med. 2013;32:2643-60. doi:10.1002/sim.5670 PMID:23124850
18. Liquet B, Timsit JF, Rondeau V. Investigating hospital heterogeneity with a multi-state frailty model: application to nosocomial pneumonia disease in intensive care units. BMC Med Res Methodol. 2012;12:79. doi:10.1186/1471-2288-12-79 PMID:22702430
19. Timsit JF. Réactualisation de la douzième conférence de consensus de la Société de réanimation de langue française (SRLF): infections liées aux cathéters veineux centraux en réanimation (Updating of the 12th consensus conference of the Société de Réanimation de langue française (SRLF): Catheter related infections in the intensive care unit). Ann Fr Anesth Reanim. 2005;24(3):315-22. doi:10.1016/j.annfar.2004.12.022 PMID:15792575.
20. Weinstein MC, Fineberg HV, Elstein AS, Frazier HS, Neuhauser D, Neutra RR. Clinical Decision Analysis. Philadelphia: WB Saunders Company; 1980.
21. Beck JR, Pauker SG. The Markov Process in Medical Prognosis. Med Decis Making. 1983;3(4):419. PMID:6668990
22. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-38. PMID:8246705
23. Janssen J, Limnios N. Semi-markov models and applications. Norwell: Kluwer Academic Publishers; 1999. 432 p.
24. Hastings WK. Monte Carlo Sampling Methods Using Markov Chains and Their Applications. Biometrika. 1970;57(1):97-109.
25. Schwebel C, Lucet JC, Vesin A, Arrault X, Calvino-Gunther S, Bouadma L, et al. Economic evaluation of chlorhexidine-impregnated sponges for preventing catheter-related infections in critically ill adults in the Dressing Study. Crit Care Med. 2012;40(1):11-7. doi:10.1097/CCM.0b013e31822f0604 PMID:21926570.
26. Garrigues B. Étude CRRéa: Évaluation médico-économique du Coût Réel d'une journée en RÉAnimation (Medico-economic evaluation of the Real Cost of a day in ICU).. http://www.snmrhp.org/Data/ModuleGestionDeContenu/application/880.pdf 2010. Accessed 30 March 2015.
27. Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. ArchSurg. 2001;136(229):234. PMID:11177147
28. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754-8. PMID:11594901
29. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice of decision analytic modeling in health care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6:9-17. PMID:12535234
30. Gelfand AE. Gibbs sampling. Journal of the American Statistical Association. 2000;95(452):1300-4.
31. Saint S, Veenstra DL, Lipsky BA. The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful? Infect Control Hosp Epidemiol. 2000;21:375-80. PMID:10879567
32. Wenzel RP, Edmond MB. The impact of hospital-acquired bloodstream infections. Emerg Infect Dis. 2001;7:174-7. PMID:11294700
33. Crawford AG, Fuhr JP, Rao B. Cost-Benefit Analysis of Chlorhexidine Gluconate Dressing in the Prevention of Catheter-Related Bloodstream Infections. Infect Control Hosp Epidemiol. 2004;25(8):668-74. PMID:15357159
34. Ye X, Rupnow M, Bastide P, Lafuma A, Ovington L, Jarvis WR. Economic impact of use of chlorhexidineimpregnated sponge dressing for prevention of central line-associated infections in the United States. Am J Infect Control. 2011;39(8):647-54. doi:10.1016/j.ajic.2010.11.008 PMID:21641681.
35. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA. 1999;282:554-60. PMID:10450717
36. Frank U, Chojnacki T, Dettenkofer M, Daschner FD. Cost-effectiveness of an antiseptic-impregnated central venous catheter in the ICU. Intensive Care Med. 2003;29:139. PMID:12528036
37. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996;5:513-24. PMID:9003938
38. Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care. 1998;14(3):467-71. PMID:9780533